Early Feasibility Study of a Transcatheter Tricuspid Valve Annuloplasty
SCOUT Trial 30-Day Results
Rebecca T. Hahn, Christopher U. Meduri, Charles J. Davidson, Scott Lim, Tamim M. Nazif, Mark J. Ricciardi, Vivek Rajagopal, Gorav Ailawadi, Mani A. Vannan, James D. Thomas, Dale Fowler, Stuart Rich, Randy Martin, Geraldine Ong, Adam Groothuis and Susheel Kodali
Transcatheter Repair System for Severe Tricuspid Regurgitation and Quality-of-Life Outcomes
The SCOUT trial is the first multicenter early feasibility study of a novel transcatheter device for functional tricuspid regurgitation that showed a significant reduction in tricuspid annular area and regurgitant orifice, with functional status and quality of life measures. (Top) Basic steps for implantation of the device. (Bottom) Changes in NYHA functional class (A), MLHFQ, (B), and 6MWT (C) are shown for the 12 patients with the device in the intended position. 6MWT = 6-min walk test; AT = as-treated population; MLHFQ = Minnesota Living with Heart Failure Questionnaire; NYHA = New York Heart Association.